Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2021-05-20 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Appendix 2A 15 pages 394.4KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities to be quoted, and references to previous announcements such as Appendix 3B. This form is a regulatory filing used to notify the exchange about new securities being issued and their quotation. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement since it contains substantive information about the securities issuance. Therefore, the document fits the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-05-20 English
IMUGENE LICENSES CAR T DIRECTED OV THERAPY FOR SOLID TUMOURS 3 pages 147.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing a licensing agreement between Imugene Ltd and City of Hope for a novel CD19 oncolytic virus technology. It discusses the terms of the license, research collaboration, and future clinical trial plans. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about a licensing deal and research collaboration, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the licensing agreement and research collaboration. Therefore, the document fits best under Capital/Financing Update (CAP) as it relates to licensing and technology acquisition which impacts the company's capital and development pipeline.
2021-05-17 English
Investor Presentation 18 pages 3.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Imugene's licensing of a novel oncolytic virus technology (CF33-CD19) to enhance CAR T therapy against solid tumors. It includes scientific data, pre-clinical study results, mechanism of action, and future clinical study plans. The content is structured as an investor or scientific presentation with disclaimers, investment highlights, and detailed scientific explanations. There is no indication that this is a regulatory filing, annual or interim report, earnings release, or any other formal financial or regulatory document. The presence of slides, disclaimers, and detailed scientific and investment highlights strongly suggests this is an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification rather than a brief announcement or report publication notice.
2021-05-17 English
Investor Webinar Details 2 pages 98.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about an upcoming investor webinar and Q&A session related to a licensing deal for a CAR T directed oncolytic virus therapy. It includes details about the webinar registration and contact information but does not contain any financial data, report content, or detailed presentation materials. The document length is short (3292 characters) and it primarily serves as an announcement of an event rather than a report or detailed investor presentation. Therefore, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous announcements that do not fit other specific categories.
2021-05-17 English
Proposed issue of Securities - IMU 5 pages 27.0KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Imugene Limited. It details the number of securities to be issued, the issue price, the class of securities, and other related information such as approvals and fees. There is no financial performance data, management discussion, or audit information. The document is focused on informing about a capital raising activity, specifically a placement or other type of issue of shares. This fits the definition of a Capital/Financing Update (CAP). The document length is about 4850 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Therefore, the appropriate classification is CAP.
2021-05-13 English
Appendix 2A 15 pages 388.0KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities to be quoted, and references to previous announcements such as Appendix 3B. The document is a regulatory form used to notify the exchange about new securities being issued and their quotation. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement since it contains substantive regulatory information and is not merely announcing the availability of a report. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to the issuance and quotation of new securities, which is a capital market activity.
2021-05-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.